Background COVID-19 Convalescent plasma (CCP) is safe and effective, particularly if given at an early stage of the disease. Our study aimed to identify an association between survival and specific antibodies found in CCP. Patients and Methods Patients ≥18 years of age who were hospitalized with moderate to severe COVID-19 infection and received CCP at the MD Anderson Cancer Center between 4/30/2020 and 8/20/2020 were included in the study. We quantified the levels of anti-SARS-CoV-2 antibodies, as well as antibodies against antigens of other coronavirus strains, in the CCP units and compared antibody levels with patient outcomes. For each antibody, a Bayesian exponential survival time regression model including prognostic variables was fit, and the posterior probability of a beneficial effect (PBE) of higher antibody level on survival time was computed. Results CCP was administered to 44 cancer patients. The median age was 60 years (range 37-84) and 19 (43%) were female. Twelve patients (27%) died of COVID-19-related complications. Higher levels of two non-SARS-CoV-2-specific antibodies, anti-HCoV-OC43 spike IgG and anti-HCoV-HKU1 spike IgG, had PBE = 1.00, and 4 SARS-CoV-2-specific antibodies had PBEs between 0.90 and 0.95. Other factors associated with better survival were shorter time to CCP administration, younger age, and female sex. Conclusions Common cold coronavirus spike IgG antibodies anti-HCoV-OC43 and anti-HCoV-HKU1 may target a common domain for SARS-CoV-2 and other coronaviruses. They provide a promising therapeutic target for monoclonal antibody production.
【저자키워드】 COVID-19, convalescent plasma, SARS-CoV-2, coronavirus antibodies, HCoV-OC43, HCoV-HKU1, 【초록키워드】 coronavirus, Bayesian, Hospitalized, antibody, monoclonal antibody, HCoV-OC43, HCoV-HKU1, Sex, Antigen, outcomes, anti-SARS-CoV-2 antibodies, survival, COVID-19 infection, IgG antibodies, Regression model, female, Patient, Cancer patients, antigens, age, antibody levels, common cold, Other, moderate, early stage, OC43, HKU1, COVID-19 convalescent plasma, spike IgG, specific antibodies, association, Safe, therapeutic target, CCP, moderate to severe, survival time, Severe COVID-19 Infection, Factor, SARS-CoV-2-specific antibody, other coronaviruses, median age, domain, posterior probability, prognostic variables, anti-HCoV-HKU1 spike IgG, anti-HCoV-OC43, anti-HCoV-OC43 spike IgG, Bayesian exponential survival time regression model, CCP administration, COVID-19-related complications, MD Anderson Cancer Center, non-SARS-CoV-2-specific antibodies, PBEs, coronavirus strains, Administered, effective, common, Result, identify, died, the disease, specific antibody, quantified, Anderson Cancer Center, PBE, prognostic variable, 【제목키워드】 Cold, common, Improved, Level,